Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas
Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.
Lymphoma
DRUG: CEEP regimen|PROCEDURE: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)
Complete response, end of treatment
overall survival disease free survival, 10 years after treatment
High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral blood stem cell support Patients were aged from 15 to 60 years